Pregled bibliografske jedinice broj: 933655
Efficacy and safety of biosimilar infliximab (Inflectra) in patients with ankylosing spondylitis: multicentre and observational one year follow-up study
Efficacy and safety of biosimilar infliximab (Inflectra) in patients with ankylosing spondylitis: multicentre and observational one year follow-up study // International Journal of Rheumatic Diseases, 20 (2017), 1; 51-51 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 933655 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Efficacy and safety of biosimilar infliximab
(Inflectra) in patients with ankylosing
spondylitis: multicentre and observational one
year follow-up study
Autori
F. Grubisic, S. Grazio, B. Anic, M. Baresic, S. Novak, F. Anic, V. Prus, A. G. Gracanin, J. Morovic Vergles, D.M. Kaliterna, K. Boric, T. Kehler
Izvornik
International Journal of Rheumatic Diseases (1756-1841) 20
(2017), 1;
51-51
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
(biosimilar, infliximab, ankylosing spondylitis)
Sažetak
The aim of the study was to evaluate the efficacy and safety of biosimilar Inflectra in patients with AS.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Rijeka,
Fakultet zdravstvenih studija u Rijeci
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
